A randomized placebo-controlled phase II study of clarithromycin or placebo combined with VCD induction therapy prior to high-dose melphalan with stem cell support in patients with newly diagnosed multiple myeloma

A randomized placebo-controlled phase II study of clarithromycin or placebo combined with VCD induction therapy prior to high-dose melphalan with stem cell support in patients with newly diagnosed multiple myeloma

Abstract Background The objective of this randomized placebo-controlled study was to investigate the efficacy and safety of clarithromycin in combination with bortezomib–cyclophosphamide–dexamethasone (VCD) in patients with newly diagnosed multiple myeloma eligible for high-dose therapy. Methods Pat...

Full description

Bibliographic Details
Main Authors: Henrik Gregersen, Trung Do, Ida Bruun Kristensen, Ulf Christian Frølund, Niels Frost Andersen, Lene Kongsgaard Nielsen, Christen Lykkegaard Andersen, Tobias Wirenfeldt Klausen, Annette Juul Vangsted, Niels Abildgaard
Format: Article
Language:English
Published: BMC 2018-08-01
Series:Experimental Hematology & Oncology
Subjects:
Multiple myeloma
Clarithromycin
Bortezomib
Adverse drug event
Induction chemotherapy
Double blind study
Online Access:http://link.springer.com/article/10.1186/s40164-018-0110-0

Internet

http://link.springer.com/article/10.1186/s40164-018-0110-0

Similar Items